Guardant Health (GH) investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175.
For Q2, according to Seeking Alpha, analysts are expecting normalized EPS of $1.28, GAAP EPS of $0.97, and $12.52bn of ...
Woman's World on MSN
Colon cancer screening guidelines changed: What women over 40 need to know
Colon cancer used to feel like a worry for later-something to think about decades down the road. Not anymore. An estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results